CD80 and cancer: Anti‐TGF‐β antibodies rendered TGF‐β‐responsive cancer stem cells sensitive to adoptive T‐cell transfer treatment, of which the efficacy could be hindered by CD80/CTLA4‐mediated immunosuppression.16